These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23700288)

  • 21. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
    Giles FJ; List AF; Carroll M; Cortes JE; Valickas J; Chen BL; Masson E; Jacques C; Laurent D; Albitar M; Feldman EJ; Roboz GJ
    Leuk Res; 2007 Jul; 31(7):891-7. PubMed ID: 17560285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Giles FJ; Bellamy WT; Estrov Z; O'Brien SM; Verstovsek S; Ravandi F; Beran M; Bycott P; Pithavala Y; Steinfeldt H; Reich SD; List AF; Yee KW
    Leuk Res; 2006 Jul; 30(7):801-11. PubMed ID: 16332390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice.
    Zips D; Hessel F; Krause M; Schiefer Y; Hoinkis C; Thames HD; Haberey M; Baumann M
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):908-14. PubMed ID: 15708274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
    Grosios K; Wood J; Esser R; Raychaudhuri A; Dawson J
    Inflamm Res; 2004 Apr; 53(4):133-42. PubMed ID: 15060719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
    Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
    Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
    Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
    Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
    Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
    Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
    Ravoet C; Mineur P; Robin V; Debusscher L; Bosly A; André M; El Housni H; Soree A; Bron D; Martiat P
    Ann Hematol; 2008 Nov; 87(11):881-5. PubMed ID: 18641985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2 study of vatalanib in metastatic melanoma patients.
    Cook N; Basu B; Biswas S; Kareclas P; Mann C; Palmer C; Thomas A; Nicholson S; Morgan B; Lomas D; Sirohi B; Mander AP; Middleton M; Corrie PG
    Eur J Cancer; 2010 Oct; 46(15):2671-3. PubMed ID: 20800475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
    Scott EN; Meinhardt G; Jacques C; Laurent D; Thomas AL
    Expert Opin Investig Drugs; 2007 Mar; 16(3):367-79. PubMed ID: 17302531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
    Goldbrunner RH; Bendszus M; Wood J; Kiderlen M; Sasaki M; Tonn JC
    Neurosurgery; 2004 Aug; 55(2):426-32; discussion 432. PubMed ID: 15271251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTK/ZK (Novartis).
    Drevs J
    IDrugs; 2003 Aug; 6(8):787-94. PubMed ID: 12917775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
    Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ
    Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.